McClung MR - Search Results

1

Tiludronate therapy for Paget's disease of bone.

McClung MR, Tou CK, Goldstein NH, Picot C. McClung MR, et al. Bone. 1995 Nov;17(5 Suppl):493S-496S. doi: 10.1016/8756-3282(95)00282-1. Bone. 1995. PMID: 8573425 Clinical Trial.

2

Current bone mineral density data on bisphosphonates in postmenopausal osteoporosis.

McClung MR. McClung MR. Bone. 1996 Nov;19(5 Suppl):195S-198S. doi: 10.1016/s8756-3282(96)90165-9. Bone. 1996. PMID: 8922662 Review.

3

Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group.

McClung M, Clemmesen B, Daifotis A, Gilchrist NL, Eisman J, Weinstein RS, Fuleihan G el-H, Reda C, Yates AJ, Ravn P. McClung M, et al. Ann Intern Med. 1998 Feb 15;128(4):253-61. doi: 10.7326/0003-4819-128-4-199802150-00001. Ann Intern Med. 1998. PMID: 9471927 Clinical Trial.

4

Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.

McClung MR, Wasnich RD, Recker R, Cauley JA, Chesnut CH 3rd, Ensrud KE, Burdeska A, Mills T; Oral Ibandronate Study Group. McClung MR, et al. J Bone Miner Res. 2004 Jan;19(1):11-8. doi: 10.1359/JBMR.0301202. J Bone Miner Res. 2004. PMID: 14753731 Free article. Clinical Trial.

5

Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.

McClung MR, Siris E, Cummings S, Bolognese M, Ettinger M, Moffett A, Emkey R, Day W, Somayaji V, Lee A. McClung MR, et al. Menopause. 2006 May-Jun;13(3):377-86. doi: 10.1097/01.gme.0000188736.69617.4f. Menopause. 2006. PMID: 16735934 Clinical Trial.

6

Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.

McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J. McClung M, et al. Bone. 2007 Jul;41(1):122-8. doi: 10.1016/j.bone.2007.03.011. Epub 2007 Mar 24. Bone. 2007. PMID: 17468062 Clinical Trial.

7

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial.

Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, Liu Y, San Martin J. Miller PD, et al. Among authors: mcclung mr. Bone. 2008 Aug;43(2):222-229. doi: 10.1016/j.bone.2008.04.007. Epub 2008 Apr 26. Bone. 2008. PMID: 18539106 Clinical Trial.

8

Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss.

McClung MR, Bolognese MA, Sedarati F, Recker RR, Miller PD. McClung MR, et al. Bone. 2009 Mar;44(3):418-22. doi: 10.1016/j.bone.2008.09.011. Epub 2008 Oct 7. Bone. 2009. PMID: 18950736 Clinical Trial.

9

Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial.

McClung M, Miller P, Recknor C, Mesenbrink P, Bucci-Rechtweg C, Benhamou CL. McClung M, et al. Obstet Gynecol. 2009 Nov;114(5):999-1007. doi: 10.1097/AOG.0b013e3181bdce0a. Obstet Gynecol. 2009. PMID: 20168099 Clinical Trial.

10

Histomorphometric effects of calcium or calcium plus 25-hydroxyvitamin D3 therapy in senile osteoporosis.

Orwoll ES, McClung MR, Oviatt SK, Recker RR, Weigel RM. Orwoll ES, et al. Among authors: mcclung mr. J Bone Miner Res. 1989 Feb;4(1):81-8. doi: 10.1002/jbmr.5650040112. J Bone Miner Res. 1989. PMID: 2718782 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

270 results

Search Page

Filters